Do you want to read an article? Please log in or register.
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
Lung, Respiratory and Thoracic Cancer
